Researchers use magnets to direct cancer drugs; Oral delivery tech could boost HIV therapy;

 @DamianFierce: Aptar Pharma has bought a French company for $207M to expand its injectable delivery offerings. Story | Follow @DamianFierce

> Researchers in Scotland and Australia have developed an iron-based nanocasing for the cancer drug Cisplatin, using small external magnets to direct the drug to its target. News

> University of British Columbia scientists have received funding from the National Research Council of Canada to investigate whether their novel oral delivery method can be paired with existing HIV treatments to boost effectiveness. Report

> Roymer Biomedical has received the FDA's OK to begin human trials of AppliGel-G, a polymer-based drug delivery platform for ulcer treatment. Story

> Using silica nanosheets, researchers in Australia have developed flake-coated nanocapsules that allow for controlled-release delivery. Article

> Israeli drug delivery company D. Medical reported a $1.2 million loss in the first quarter, and the company plans to seek outside investment until it can subsist on its revenue. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.